Literature DB >> 2843678

Inability of Kaplan radiation leukemia virus to replicate on mouse fibroblasts is conferred by its long terminal repeat.

E Rassart1, Y Paquette, P Jolicoeur.   

Abstract

The molecularly cloned infectious Kaplan radiation leukemia virus has previously been shown to be unable to replicate on mouse fibroblasts (E. Rassart, M. Shang, Y. Boie, and P. Jolicoeur, J. Virol. 58:96-106, 1986). To map the viral sequences responsible for this, we constructed chimeric viral DNA genomes in vitro with parental cloned infectious viral DNAs from the nonfibrotropic (F-) BL/VL3 V-13 radiation leukemia virus and the fibrotropic (F+) endogenous BALB/c or Moloney murine leukemia viruses (MuLV). Infectious chimeric MuLVs, recovered after transfection of Ti-6 lymphocytes with these recombinant DNAs, were tested for capacity to replicate on mouse fibroblasts in vitro. We found that chimeric MuLVs harboring the long terminal repeat (LTR) of a fibrotropic MuLV replicated well on mouse fibroblasts. Conversely, chimeric MuLVs harboring the LTR of a nonfibrotropic MuLV were restricted on mouse fibroblasts. These results indicate that the LTR of BL/VL3 radiation leukemia virus harbors the primary determinant responsible for its inability to replicate on mouse fibroblasts in vitro. Our results also show that the primary determinant allowing F+ MuLVs (endogenous BALB/c and Moloney MuLVs) to replicate on mouse fibroblasts in vitro resides within the LTR.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843678      PMCID: PMC253530          DOI: 10.1128/JVI.62.10.3840-3848.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Tissue selectivity of murine leukemia virus infection is determined by long terminal repeat sequences.

Authors:  C A Rosen; W A Haseltine; J Lenz; R Ruprecht; M W Cloyd
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

2.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

3.  Nucleotide sequence of AKV murine leukemia virus.

Authors:  W Herr
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

4.  Construction of recombinants between molecular clones of murine retrovirus MCF 247 and Akv: determinant of an in vitro host range property that maps in the long terminal repeat.

Authors:  C A Holland; J Wozney; P A Chatis; N Hopkins; J W Hartley
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

5.  Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation.

Authors:  H Potter; L Weir; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

6.  Mapping the viral sequences conferring leukemogenicity and disease specificity in Moloney and amphotropic murine leukemia viruses.

Authors:  L DesGroseillers; P Jolicoeur
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

7.  Integration of type B retroviral DNA in virus-induced primary murine thymic lymphomas.

Authors:  G A Dekaban; J K Ball
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

8.  A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses.

Authors:  M R Lander; S K Chattopadhyay
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

9.  Envelope gene and long terminal repeat determine the different biological properties of Rauscher, Friend, and Moloney mink cell focus-inducing viruses.

Authors:  M Vogt; C Haggblom; S Swift; M Haas
Journal:  J Virol       Date:  1985-07       Impact factor: 5.103

10.  Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses.

Authors:  L DesGroseillers; P Jolicoeur
Journal:  J Virol       Date:  1983-12       Impact factor: 5.103

View more
  8 in total

1.  Point mutations in the Moloney murine leukemia virus enhancer identify a lymphoid-specific viral core motif and 1,3-phorbol myristate acetate-inducible element.

Authors:  N A Speck; B Renjifo; N Hopkins
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  DNA-binding proteins that interact with the long terminal repeat of radiation leukemia virus.

Authors:  I Gorska-Flipot; P Jolicoeur
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  Determinants of thymotropism in Kaplan radiation leukemia virus and nucleotide sequence of its envelope region.

Authors:  L Poliquin; D Bergeron; J L Fortier; Y Paquette; R Bergeron; E Rassart
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  Graffi murine leukemia virus: molecular cloning and characterization of the myeloid leukemia-inducing agent.

Authors:  M Ru; C Shustik; E Rassart
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

5.  The majority of cells infected with the defective murine AIDS virus belong to the B-cell lineage.

Authors:  M Huang; C Simard; D G Kay; P Jolicoeur
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

6.  The E47 transcription factor binds to the enhancer sequences of recombinant murine leukemia viruses and influences enhancer function.

Authors:  S C Lawrenz-Smith; C Y Thomas
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  U3 long terminal repeat-mediated induction of intracellular immunity by a murine retrovirus: a novel model of latency for retroviruses.

Authors:  I Gorska-Flipot; M Huang; M Cantin; E Rassart; G Massé; P Jolicoeur
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Mutational analysis of the murine AIDS-defective viral genome reveals a high reversion rate in vivo and a requirement for an intact Pr60gag protein for efficient induction of disease.

Authors:  M Huang; Z Hanna; P Jolicoeur
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.